Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.57 USD | -0.77% | +2.80% | +91.79% |
May. 07 | Transcript : Trevi Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 | |
May. 07 | Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 181M |
---|---|---|---|---|---|
Net income 2024 * | -43M | Net income 2025 * | -53M | EV / Sales 2024 * | - |
Net cash position 2024 * | 107M | Net cash position 2025 * | 188M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.01
x | P/E ratio 2025 * |
-5.59
x | Employees | 25 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.72% |
Latest transcript on Trevi Therapeutics, Inc.
1 day | -0.77% | ||
1 week | +2.80% | ||
1 month | -12.29% | ||
3 months | -11.99% | ||
6 months | +128.44% | ||
Current year | +91.79% |
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Good
FOU | Founder | 59 | 11-02-28 |
Thomas Sciascia
FOU | Founder | 70 | 10-12-31 |
Lisa Delfini
DFI | Director of Finance/CFO | 54 | 21-08-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anne VanLent
BRD | Director/Board Member | 76 | 18-10-09 |
James Cassella
BRD | Director/Board Member | 69 | 20-02-12 |
Jennifer Good
FOU | Founder | 59 | 11-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +3.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 2.57 | -0.77% | 80,207 |
24-05-30 | 2.59 | +1.97% | 303,124 |
24-05-29 | 2.54 | -0.78% | 199,697 |
24-05-28 | 2.56 | +2.40% | 218,124 |
24-05-24 | 2.5 | -1.57% | 431,990 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+91.79% | 181M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- TRVI Stock